Your session is about to expire
← Back to Search
Gemcitabine Hydrochloride for Renal Pelvis and Ureter Cancer
Study Summary
This trial is studying gemcitabine to see if it can prevent urothelial cancer from recurring in the bladder for patients with upper urinary tract urothelial cancer.
- Renal Pelvis and Ureter Cancer
- Ureter Cancer
- Renal Pelvis Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2013 Phase 3 trial • 4312 Patients • NCT00011986Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Will patients experience any dangerous side-effects from Gemcitabine Hydrochloride?
"While Phase 2 trials are not as reliable in terms of evidence, our team believes that Gemcitabine Hydrochloride is safe enough to be given a score of 2."
Are there precedent studies which have utilized Gemcitabine Hydrochloride?
"464 studies are currently investigating gemcitabine hydrochloride. Of these ongoing research projects, 137 have reached phase 3. The majority of these trials for gemcitabine hydrochloride are based in Adelaide, South Australia; however, 24669 other locations worldwide are also running similar investigations."
How many people are currently signed up to participate in this trial?
"This specific study is not recruiting any more patients. However, if you are looking for other trials, there are presently 178 trials actively admitting patients with malignant neoplasm of ureter and 464 studies for Gemcitabine Hydrochloride that still need participants."
Is Gemcitabine Hydrochloride used to help patients with cancer?
"small cell lung cancer (sclc) is most often treated with Gemcitabine Hydrochloride. However, this medication can also target head and neck carcinoma, pancreatic adenocarcinoma locally advanced, and cervical cancers."
Are there many hospitals participating in this trial throughout the state?
"The research is being conducted at University of Pittsburgh Cancer Institute (UPCI), Wake Forest Baptist Medical Center, Mayo Clinic in Rochester and 7 other locations."
Are there any vacancies in this study for new test subjects?
"As of July 5th, 2022, this clinical trial is no longer recruiting patients. The posting for the trial was first made on June 5th, 2020. If you are looking for other trials, there are presently 178 clinical trials actively recruiting participants with malignant neoplasm of ureter and 464 trials for Gemcitabine Hydrochloride enrolling patients."
Share this study with friends
Copy Link
Messenger